|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 25.86 EUR | -1.52% |
|
-2.56% | -63.58% |
| 12-05 | Schott Pharma at record low after weak targets | DP |
| 12-05 | Schott Pharma Takes Cautious View on 2026 - Shares Drop | DP |
| Capitalization | 893M 1.04B 837M 780M 1.44B 93.52B 1.57B 9.79B 3.78B 44.17B 3.9B 3.82B 161B | P/E ratio 2025 * |
47.7x | P/E ratio 2026 * | 14.2x |
|---|---|---|---|---|---|
| Enterprise value | 2.94B 3.42B 2.75B 2.56B 4.74B 307B 5.15B 32.18B 12.43B 145B 12.82B 12.55B 531B | EV / Sales 2025 * |
1.27x | EV / Sales 2026 * | 1.18x |
| Free-Float |
96.72% | Yield 2025 * |
2.04% | Yield 2026 * | 2.81% |
Last Transcript: Gerresheimer AG
| 1 day | -1.52% | ||
| 1 week | -2.56% | ||
| Current month | -2.56% | ||
| 1 month | +1.49% | ||
| 3 months | -37.29% | ||
| 6 months | -47.37% | ||
| Current year | -63.58% |
| 1 week | 25.38 |  | 27.36 |
| 1 month | 23 | | 27.36 |
| Current year | 23 | | 85.25 |
| 1 year | 23 | | 85.25 |
| 3 years | 23 | | 122.9 |
| 5 years | 23 | | 122.9 |
| 10 years | 23 | | 122.9 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 63 | 22/06/2010 | |
Wolf Uwe Lehmann
DFI | Director of Finance/CFO | 54 | 01/09/2025 |
Guido Pickert
IRC | Investor Relations Contact | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Francesco Grioli
BRD | Director/Board Member | 53 | 01/01/2011 |
Axel Herberg
CHM | Chairman | 67 | 30/04/2015 |
Markus Rocholz
BRD | Director/Board Member | 55 | 26/04/2012 |
| Name | Weight | AuM | Varia. Jan 1. | Investor |
|---|---|---|---|---|
 | 2.97% | 0 M€ | -.--% | - |
| 0.23% | 0 M€ | -.--% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -1.52% | -2.56% | -65.52% | -63.50% | 1.04B | |
| -0.26% | -2.96% | +8.21% | +18.66% | 217B | |
| -0.62% | -3.77% | +20.47% | +28.65% | 130B | |
| +0.60% | -7.93% | +39.03% | +98.31% | 65.89B | |
| +0.10% | -0.03% | -12.72% | -21.22% | 55.36B | |
| +0.25% | +1.92% | +18.79% | +71.57% | 52.03B | |
| +0.87% | -1.13% | +21.09% | +41.95% | 25.84B | |
| +0.37% | +3.18% | -17.02% | -43.81% | 25.54B | |
| -0.33% | +2.89% | +21.71% | -36.74% | 24.14B | |
| -2.23% | -2.91% | -24.00% | +17.39% | 22.48B | |
| Average | -0.28% | -1.33% | +1.00% | +11.13% | 61.98B | |
| Weighted average by Cap. | -0.17% | -2.43% | +11.81% | +26.16% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 2.32B 2.7B 2.17B 2.02B 3.74B 243B 4.07B 25.39B 9.81B 115B 10.12B 9.9B 419B | 2.42B 2.81B 2.26B 2.11B 3.9B 253B 4.24B 26.49B 10.23B 120B 10.56B 10.33B 437B |
| Net income | 18.65M 21.7M 17.47M 16.29M 30.08M 1.95B 32.72M 204M 78.92M 922M 81.44M 79.71M 3.37B | 62.47M 72.67M 58.52M 54.54M 101M 6.54B 110M 684M 264M 3.09B 273M 267M 11.29B |
| Net Debt | 2.04B 2.38B 1.91B 1.78B 3.3B 214B 3.58B 22.39B 8.65B 101B 8.92B 8.73B 369B | 1.95B 2.27B 1.83B 1.71B 3.15B 205B 3.43B 21.41B 8.27B 96.64B 8.53B 8.35B 353B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 05/12/25 | 25.86 € | -1.45% | 198,141 |
| 04/12/25 | 26.24 € | +0.54% | 176,179 |
| 03/12/25 | 26.10 € | +1.87% | 211,427 |
| 02/12/25 | 25.62 € | -4.12% | 240,595 |
| 01/12/25 | 26.72 € | +0.68% | 206,447 |
Delayed Quote Xetra, December 05, 2025 at 07:37 pm
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- GXI Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition